These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 37439680)

  • 1. Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer.
    Traphagen NA; Schwartz GN; Tau S; Roberts AM; Jiang A; Hosford SR; Marotti JD; Goen AE; Romo BA; Johnson AL; Duffy EK; Demidenko E; Heverly P; Mosesson Y; Soucy SM; Kolling F; Miller TW
    Clin Cancer Res; 2023 Sep; 29(18):3717-3728. PubMed ID: 37439680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen therapy induces receptor-dependent DNA damage enhanced by PARP inhibition in ER+ breast cancer.
    Traphagen NA; Schwartz GN; Tau S; Jiang A; Hosford SR; Goen AE; Roberts AM; Romo BA; Johnson AL; Duffy EK; Demidenko E; Heverly P; Mosesson Y; Soucy SM; Kolling F; Miller TW
    bioRxiv; 2023 Mar; ():. PubMed ID: 36993590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells.
    Arun B; Akar U; Gutierrez-Barrera AM; Hortobagyi GN; Ozpolat B
    Int J Oncol; 2015 Jul; 47(1):262-8. PubMed ID: 25975349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poly(ADP-ribose) polymerase as a novel regulator of 17β-estradiol-induced cell growth through a control of the estrogen receptor/IGF-1 receptor/PDZK1 axis.
    Kim H; Tarhuni A; Abd Elmageed ZY; Boulares AH
    J Transl Med; 2015 Jul; 13():233. PubMed ID: 26183824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PRMT5 Inhibitors Regulate DNA Damage Repair Pathways in Cancer Cells and Improve Response to PARP Inhibition and Chemotherapies.
    Carter J; Hulse M; Sivakumar M; Burtell J; Thodima V; Wang M; Agarwal A; Vykuntam K; Spruance J; Bhagwat N; Rager J; Ruggeri B; Scherle P; Ito K
    Cancer Res Commun; 2023 Nov; 3(11):2233-2243. PubMed ID: 37861290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARP-1 Regulates Estrogen-Dependent Gene Expression in Estrogen Receptor α-Positive Breast Cancer Cells.
    Gadad SS; Camacho CV; Malladi V; Hutti CR; Nagari A; Kraus WL
    Mol Cancer Res; 2021 Oct; 19(10):1688-1698. PubMed ID: 34158394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancer.
    Saatci O; Cetin M; Uner M; Tokat UM; Chatzistamou I; Ersan PG; Montaudon E; Akyol A; Aksoy S; Uner A; Marangoni E; Sajish M; Sahin O
    Nat Commun; 2023 Nov; 14(1):6997. PubMed ID: 37914699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of estrogen-dependent transactivation vs. transrepression by the estrogen receptor on invasiveness of HER2 overexpressing breast cancer cells.
    Patki M; Salazar Md; Trumbly R; Ratnam M
    Biochem Biophys Res Commun; 2015 Feb; 457(3):404-11. PubMed ID: 25582774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
    Cruz C; Castroviejo-Bermejo M; Gutiérrez-Enríquez S; Llop-Guevara A; Ibrahim YH; Gris-Oliver A; Bonache S; Morancho B; Bruna A; Rueda OM; Lai Z; Polanska UM; Jones GN; Kristel P; de Bustos L; Guzman M; Rodríguez O; Grueso J; Montalban G; Caratú G; Mancuso F; Fasani R; Jiménez J; Howat WJ; Dougherty B; Vivancos A; Nuciforo P; Serres-Créixams X; Rubio IT; Oaknin A; Cadogan E; Barrett JC; Caldas C; Baselga J; Saura C; Cortés J; Arribas J; Jonkers J; Díez O; O'Connor MJ; Balmaña J; Serra V
    Ann Oncol; 2018 May; 29(5):1203-1210. PubMed ID: 29635390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.
    Ibrahim YH; García-García C; Serra V; He L; Torres-Lockhart K; Prat A; Anton P; Cozar P; Guzmán M; Grueso J; Rodríguez O; Calvo MT; Aura C; Díez O; Rubio IT; Pérez J; Rodón J; Cortés J; Ellisen LW; Scaltriti M; Baselga J
    Cancer Discov; 2012 Nov; 2(11):1036-47. PubMed ID: 22915752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PSPC1 Inhibition Synergizes with Poly(ADP-ribose) Polymerase Inhibitors in a Preclinical Model of BRCA-Mutated Breast/Ovarian Cancer.
    Ghosh M; Kang MS; Katuwal NB; Hong SD; Jeong YG; Park SM; Kim SG; Moon YW
    Int J Mol Sci; 2023 Dec; 24(23):. PubMed ID: 38069409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2,3,7,8-Tetrachlorodibenzo-p-dioxin modulates the induction of DNA strand breaks and poly(ADP-ribose) polymerase-1 activation by 17beta-estradiol in human breast carcinoma cells through alteration of CYP1A1 and CYP1B1 expression.
    Lin PH; Lin CH; Huang CC; Fang JP; Chuang MC
    Chem Res Toxicol; 2008 Jul; 21(7):1337-47. PubMed ID: 18558727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells.
    Schoonen PM; Talens F; Stok C; Gogola E; Heijink AM; Bouwman P; Foijer F; Tarsounas M; Blatter S; Jonkers J; Rottenberg S; van Vugt MATM
    Nat Commun; 2017 Jul; 8():15981. PubMed ID: 28714471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.
    Clark CC; Weitzel JN; O'Connor TR
    Mol Cancer Ther; 2012 Sep; 11(9):1948-58. PubMed ID: 22778154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer.
    Liu Y; Burness ML; Martin-Trevino R; Guy J; Bai S; Harouaka R; Brooks MD; Shang L; Fox A; Luther TK; Davis A; Baker TL; Colacino J; Clouthier SG; Shao ZM; Wicha MS; Liu S
    Clin Cancer Res; 2017 Jan; 23(2):514-522. PubMed ID: 28034904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
    Turk AA; Wisinski KB
    Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy of PARP inhibitors in breast cancer.
    Pandya K; Scher A; Omene C; Ganesan S; Kumar S; Ohri N; Potdevin L; Haffty B; Toppmeyer DL; George MA
    Breast Cancer Res Treat; 2023 Jul; 200(1):15-22. PubMed ID: 37129747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diverse
    Weigelt B; Comino-Méndez I; de Bruijn I; Tian L; Meisel JL; García-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY; Lim RS; Selenica P; Piscuoglio S; Aghajanian C; Norton L; Murali R; Hyman DM; Borsu L; Arcila ME; Konner J; Reis-Filho JS; Greenberg RA; Robson ME; Turner NC
    Clin Cancer Res; 2017 Nov; 23(21):6708-6720. PubMed ID: 28765325
    [No Abstract]   [Full Text] [Related]  

  • 19. A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells.
    Senhaji Mouhri Z; Goodfellow E; Jean-Claude B
    BMC Cancer; 2017 Aug; 17(1):540. PubMed ID: 28800752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides
    Voutsadakis IA; Stravodimou A
    Anticancer Res; 2023 Mar; 43(3):967-981. PubMed ID: 36854505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.